Medicare IVIG Access Enhancement Act of 2025
Sponsored By: Representative Smith, Adrian [R-NE-3]
Introduced
Summary
Expands Medicare in-home IVIG coverage to treat CIDP and MPN. This bill would let Medicare cover intravenous immune globulin given at home for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. It also authorizes different payment levels by diagnosis, set by the Secretary through notice-and-comment rulemaking.
Show full summary
- People with CIDP or MPN on Medicare would become eligible for Medicare-covered in-home IVIG beginning January 1, 2027, which can reduce travel to infusion centers and clinic visits.
- Family caregivers and home-infusion providers could see more IVIG delivered at home, changing care routines and billing needs for those services.
- Medicare payment policy would change because the Secretary must establish diagnosis-based payment variations for in-home IVIG through formal rulemaking, allowing different rates for primary immune deficiency versus CIDP or MPN.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Medicare in-home IVIG for CIDP and MMN
If enacted, Medicare would cover in-home IVIG to treat chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). Coverage would start January 1, 2027. This applies to IVIG given at home for these diagnoses. The bill does not set payment amounts or cost-sharing rules.
Medicare may vary in-home IVIG payments
If enacted, Medicare could pay different amounts for in-home IVIG based on the diagnosis. The Health and Human Services Secretary would set the differences through notice-and-comment rulemaking. The bill does not set exact rates or an effective date. Beneficiary coinsurance could change depending on the final rules.
Sponsors & CoSponsors
Sponsor
Smith, Adrian [R-NE-3]
NE • R
Cosponsors
Rep. Garamendi, John [D-CA-8]
CA • D
Sponsored 2/7/2025
Rep. Vindman, Eugene Simon [D-VA-7]
VA • D
Sponsored 11/4/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov